EUVIMEDEUVIMED entdecken
Crossref

The protective role of deferoxamine in the prevention of doxorubicin-induced hepatic fibrosis in children: A randomized controlled clinical trial

Mohammadreza Bordbar, Gholamreza Fathpour, Seyed Mohsen Dehghani, Sezaneh Haghpanah, Hossein Molavi Vardanjani, Mohammadreza Fattahi, Mahdi Shahriari, Nader Shakibazad

Iranian Journal of Blood and Cancer · 2022

DOI: 10.58209/ijbc.14.3.1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iranian Journal of Blood and Cancer, 2022. Verfasst von Mohammadreza Bordbar und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Bordbar, M., Fathpour, G., Dehghani, S. M., Haghpanah, S., Vardanjani, H. M., Fattahi, M., Shahriari, M., & Shakibazad, N. (2022). The protective role of deferoxamine in the prevention of doxorubicin-induced hepatic fibrosis in children: A randomized controlled clinical trial. Iranian Journal of Blood and Cancer. https://doi.org/10.58209/ijbc.14.3.1

Vancouver

Bordbar M, Fathpour G, Dehghani SM, Haghpanah S, Vardanjani HM, Fattahi M, et al. The protective role of deferoxamine in the prevention of doxorubicin-induced hepatic fibrosis in children: A randomized controlled clinical trial. Iranian Journal of Blood and Cancer. 2022. doi:10.58209/ijbc.14.3.1

BibTeX
@article{Bordbar2022,
  author = {Bordbar, Mohammadreza and Fathpour, Gholamreza and Dehghani, Seyed Mohsen and Haghpanah, Sezaneh and Vardanjani, Hossein Molavi and Fattahi, Mohammadreza and Shahriari, Mahdi and Shakibazad, Nader},
  title = {The protective role of deferoxamine in the prevention of doxorubicin-induced hepatic fibrosis in children: A randomized controlled clinical trial},
  journal = {Iranian Journal of Blood and Cancer},
  year = {2022},
  doi = {10.58209/ijbc.14.3.1}
}
Kostenlos starten →